North America Knee Osteoarthritis (OA) Injectable Treatments Market Size is USD 1.48 Billion in 2026

North America Knee Osteoarthritis (OA) Injectable Treatments Market (By Product Type: Viscosupplements, Stem Cell Therapy Injections, Botulinum Toxin Injections, Combination Injections, and Other Biologic Injections; By Mechanism of Action: Lubrication, Anti-inflammatory, and Regenerative; By Disease Severity: Mild Knee OA, Moderate Knee OA, and Severe Knee OA; By Age Group: 40–60 Years and 60 Years & Above; By Duration/Dosing Frequency: Weekly over 3–5 Weeks, Multiple Dose Regimen, Single-Dose Therapy, and Monthly; By End Use: Orthopedic Clinics, Hospitals, Ambulatory Surgical Centers (ASCs), Sports Medicine Clinics, and Research Institutes/Regenerative Medicine Centers) Industry Size, Share, Growth, Trends 2025 to 2035

Report Code : 656 | Published : 12 May 2026 | Delivery : Immediate | Format : Excel | Author : Aditi Shivarkar, Aman Singh

Revenue,

USD 1.39 Bn

Forecast Year,

USD 2.61 Bn

CAGR, 2026 - 2035

6.50%

Report Coverage

North America

Download Databook

The North America knee osteoarthritis (OA) injectable treatments market size surpassed USD 1.39 billion in 2025 and is predicted to reach around USD 2.61 billion by 2035, registering a CAGR of 6.5% from 2026 to 2035. The growing prevalence of chronic diseases and advanced healthcare structures is boosting the market.

North America Knee Osteoarthritis (OA) Injectable Treatments Market Statical Scope

Reports Attributes	Statistics
Market Size in 2025	USD 1.39 Billion
Market Size in 2026	USD 1.48 Billion
Market Size by 2035	USD 2.61 Billion
CAGR 2026 to 2035	6.50%
Base Year	2025
Forecast Period	2026 to 2035

The North America knee osteoarthritis (OA) injectable treatments market is driven an aging population, the increasing prevalence of osteoarthritis , and the ongoing production of new injectable therapies. A supportive regulatory environment and the timely availability of new treatments further enhance the region's leadership in this market. The FDA and various organizations have acknowledged the positive long-term outcomes associated with Zilretta, an extended-release corticosteroid injection, particularly among diabetic patients with osteoarthritis, as demonstrated in a 37-site Phase 3 trial.

Major market players, including Teva Pharmaceuticals, Zimmer Biomet, and Ferring Pharmaceuticals Inc., reinforce the region's strong position. Strategic initiatives, such as therapeutic study trials, mergers, acquisitions, and partnerships among pharmaceutical giants, are actively shaping the competitive landscape.

Segments	Shares (%)
Viscosupplements	45%
Stem Cell Therapy Injections	25%
Botulinum Toxin Injections	12%
Combination Injections	10%
Other Biologic Injections	8%

Viscosupplements - viscosupplements are the injectable treatments that provide joint lubrication to ease pain and improve mobility. Viscosupplements dominated with 45.00% share due to their significant use in treating knee OA and proven effectiveness in reducing pain.
Stem Cell Therapy Injections - these Injections aimed at regenerating cartilage and promoting tissue healing. The stem cell therapy injection segment held 25.00% share due to rising interest in cartilage regenerative treatments.
Botulinum Toxin Injections - these injections are used to reduce muscle spasm and pain in knee OA patients. The botulinum toxin injections segment held 12.00% share due to its specific therapeutic application and modulation of pain sensitization.

Segments	Shares (%)
Lubrication	50%
Anti-inflammatory	30%
Regenerative	20%

Lubrication - Provides joint fluid to alleviate pain and improve movement. The lubrication segment dominated with 50.00% share due to its direct effectiveness in enhancing mobility and decreasing pain for knee OA patients.
Anti-inflammatory - By the anti-inflammatory mechanism, injectables reduce inflammation and pain in knee OA. The anti-inflammatory segment held 30.00% share due to its strong therapeutic effects and the need to manage chronic joint inflammation.

Segments	Shares (%)
Moderate Knee OA	40%
Severe Knee OA	40%
Mild Knee OA	20%

Moderate Knee OA - Mid-stage osteoarthritis with more consistent pain and moderate joint damage. The moderate segment dominated with 40.00% share, driven by growing demand for injectable treatments that address more frequent pain and mobility issues.
Severe Knee OA - It is advanced OA with significant pain and joint degeneration. The severe knee OA segment held 40.00% share due to a high need for effective treatments, targeting non-surgical candidates with advanced pain.

Segments	Shares (%)
40–60 Years	50%
> 60 years	35%

40–60 Years - Patients in the prime age group with moderate knee OA symptoms. The 40-60 years segment dominated with 50.00% share due to the higher incidence of OA in this demographic and growing treatment demand.
> 60 years - Older patients with advanced knee OA typically need more aggressive and advanced treatment. This segment Held 35.00% share as OA is more common in older populations. Viscosupplements and corticosteroids are the primary treatments for this age group.

Segments	Shares (%)
Weekly over 3–5 weeks	25%
Multiple dose regimen	35%
Single-Dose Therapy	20%
Monthly	20%

Weekly over 3–5 weeks - A treatment regimen that includes weekly injections over a period of 3-5 weeks. This segment held with 25.00% share due to its established effectiveness in treating moderate to severe knee OA, and it is highly common for the management of moderate pain.
Multiple dose regimen - Treatment with several injections over a period, the multiple dose regimen held 35.00% share as it provides a balance of efficacy and convenience for patients. It mainly includes a series of 3–5 hyaluronic acid (HA) or platelet-rich plasma (PRP) injections.

Segments	Shares (%)
Orthopedic clinics	30%
Hospitals	40%
Ambulatory Surgical Centers (ASCs)	15%
Sports Medicine Clinics	10%
Research Institutes / Regenerative Medicine Centers	5%

Orthopedic clinics - Specialized clinics focused on musculoskeletal treatments. The orthopedic clinics segment is dominated with 30.00% share due to high specialization and patient trust in focused care for knee OA and the increasing popularity of regenerative medicine.
Hospitals - Hospitals are centers that provide comprehensive diagnostic and treatment services for knee OA. The hospitals segment held 40.00% share due to the high volume of patients and various treatment options provided.

Top Companies in the U.S. Insulin Drugs and Delivery Devices Market

Alcon, Inc.
Allergan plc
Anika Therapeutics, Inc.
Arthrex, Inc.
Bioventus, Inc.
Ferring Pharmaceuticals Inc.
Fidia Farmaceutici S.p.A.
Flexion Therapeutics, Inc.
Galderma S.A.
Hyaltech Ltd.
Landec Corporation (LifeCore Biomedical, Inc.)
Meiji Seika Pharma Ltd.
Merz Pharmaceuticals GmbH (Merz Aesthetics, Inc.)
OrthogenRx, Inc.
Roche Holding AG (F. Hoffmann-La Roche AG)
Royal Biologics
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Zimmer Biomet

Segments Covered in the Report

By Product Type

Viscosupplements
Stem Cell Therapy Injections
Botulinum Toxin Injections
Combination Injections
Other Biologic Injections

By Mechanism of Action

Lubrication
Anti-inflammatory
Regenerative

By Disease Severity

Moderate Knee OA
Severe Knee OA
Mild Knee OA

By Age Group

40–60 Years
60 years

By Duration/Dosing Frequency

Weekly over 3–5 weeks
Multiple dose regimen
Single-Dose Therapy
Monthly

By End Use

Orthopedic clinics
Hospitals
Ambulatory Surgical Centers (ASCs)
Sports Medicine Clinics
Research Institutes / Regenerative Medicine Centers

List of Tables & Figures

List of Tables

Table 1: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Product Type, 2025-2035 (USD Billion)
Table 2: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Mechanism of Action, 2025-2035 (USD Billion)
Table 3: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Disease Severity, 2025-2035 (USD Billion)
Table 4: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Age Group, 2025-2035 (USD Billion)
Table 5: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Duration/Dosing Frequency, 2025-2035 (USD Billion)
Table 6: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by End Use, 2025-2035 (USD Billion)
Table 7: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Viscosupplements, 2025-2035 (USD Billion)
Table 8: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Stem Cell Therapy Injections, 2025-2035 (USD Billion)
Table 9: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Botulinum Toxin Injections, 2025-2035 (USD Billion)
Table 10: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Combination Injections, 2025-2035 (USD Billion)
Table 11: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Other Biologic Injections, 2025-2035 (USD Billion)
Table 12: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Lubrication, 2025-2035 (USD Billion)
Table 13: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Anti-inflammatory, 2025-2035 (USD Billion)
Table 14: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Regenerative, 2025-2035 (USD Billion)
Table 15: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Moderate Knee OA, 2025-2035 (USD Billion)
Table 16: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Severe Knee OA, 2025-2035 (USD Billion)
Table 17: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Mild Knee OA, 2025-2035 (USD Billion)
Table 18: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by 40-60 Years, 2025-2035 (USD Billion)
Table 19: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by 60 Years, 2025-2035 (USD Billion)
Table 20: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Weekly over 3-5 Weeks, 2025-2035 (USD Billion)
Table 21: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Multiple Dose Regimen, 2025-2035 (USD Billion)
Table 22: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Single-Dose Therapy, 2025-2035 (USD Billion)
Table 23: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Monthly, 2025-2035 (USD Billion)
Table 24: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Orthopedic Clinics, 2025-2035 (USD Billion)
Table 25: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Hospitals, 2025-2035 (USD Billion)
Table 26: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Ambulatory Surgical Centers (ASCs), 2025-2035 (USD Billion)
Table 27: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Sports Medicine Clinics, 2025-2035 (USD Billion)
Table 28: North America Knee Osteoarthritis (OA) Injectable Treatments Market Size, by Research Institutes / Regenerative Medicine Centers, 2025-2035 (USD Billion)

List of Figures

Figure 1: North America Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Product Type, 2025 (%)
Figure 2: North America Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Mechanism of Action, 2025 (%)
Figure 3: North America Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Disease Severity, 2025 (%)
Figure 4: North America Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Age Group, 2025 (%)
Figure 5: North America Knee Osteoarthritis (OA) Injectable Treatments Market Share, by Duration/Dosing Frequency, 2025 (%)
Figure 6: North America Knee Osteoarthritis (OA) Injectable Treatments Market Share, by End Use, 2025 (%)
Figure 7: North America Knee Osteoarthritis (OA) Injectable Treatments Market Forecast, 2025-2035 (USD Billion)
Figure 8: Viscosupplements Segment Market Forecast, 2025-2035 (USD Billion)
Figure 9: Stem Cell Therapy Injections Segment Market Forecast, 2025-2035 (USD Billion)
Figure 10: Botulinum Toxin Injections Segment Market Forecast, 2025-2035 (USD Billion)
Figure 11: Combination Injections Segment Market Forecast, 2025-2035 (USD Billion)
Figure 12: Other Biologic Injections Segment Market Forecast, 2025-2035 (USD Billion)
Figure 13: Lubrication Segment Market Forecast, 2025-2035 (USD Billion)
Figure 14: Anti-inflammatory Segment Market Forecast, 2025-2035 (USD Billion)
Figure 15: Regenerative Segment Market Forecast, 2025-2035 (USD Billion)
Figure 16: Moderate Knee OA Segment Market Forecast, 2025-2035 (USD Billion)
Figure 17: Severe Knee OA Segment Market Forecast, 2025-2035 (USD Billion)
Figure 18: Mild Knee OA Segment Market Forecast, 2025-2035 (USD Billion)
Figure 19: 40-60 Years Segment Market Forecast, 2025-2035 (USD Billion)
Figure 20: 60 Years Segment Market Forecast, 2025-2035 (USD Billion)
Figure 21: Weekly over 3-5 Weeks Segment Market Forecast, 2025-2035 (USD Billion)
Figure 22: Multiple Dose Regimen Segment Market Forecast, 2025-2035 (USD Billion)
Figure 23: Single-Dose Therapy Segment Market Forecast, 2025-2035 (USD Billion)
Figure 24: Monthly Segment Market Forecast, 2025-2035 (USD Billion)
Figure 25: Orthopedic Clinics Segment Market Forecast, 2025-2035 (USD Billion)
Figure 26: Hospitals Segment Market Forecast, 2025-2035 (USD Billion)
Figure 27: Ambulatory Surgical Centers (ASCs) Segment Market Forecast, 2025-2035 (USD Billion)
Figure 28: Sports Medicine Clinics Segment Market Forecast, 2025-2035 (USD Billion)
Figure 29: Research Institutes / Regenerative Medicine Centers Segment Market Forecast, 2025-2035 (USD Billion)

Research Methodology

Related Databooks

March 2026